OSAKA -- Sumitomo Pharma will lay off about 400 employees at its U.S. subsidiary in March, the company announced on Monday, on slow sales and the end of the exclusivity period for its schizophrenia drug Latuda.
Pharmaceuticals
Sumitomo Pharma to cut 400 jobs at U.S. subsidiary
Move comes amid slow sales as company eyes net loss for second straight year
Sumitomo Pharma's Osaka office. The company had announced a previous round of layoffs at its U.S. subsidiary last July. (Photo by Atsushi Ooka)
Read Next
Latest on Pharmaceuticals
